• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

    9/2/25 1:30:00 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $QGEN alert in real time by email
    • U.S. market entry set to begin for QIAstat-Dx Rise – a version of QIAstat-Dx for syndromic testing that combines unparalleled throughput with the easiest workflow
    • QIAstat-Dx Rise launch can process up to 160 samples per day, initial launch includes Respiratory Panel Plus and Respiratory Panel Mini and additional panels in development
    • Expansion of QIAstat-Dx instrument portfolio in the U.S. builds on the availability of both system options in Europe and other regions of the world

    QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled throughput with the easiest workflow available to customers worldwide.

    The new system, which received clearance from the U.S. Food and Drug Administration (FDA), is designed to meet the needs of hospitals and reference laboratories seeking highly automated syndromic testing with automated loading and unloading of cartridges, access to priority handling of urgent samples and only a minimum of hands-on time.

    "The launch of QIAstat-Dx Rise marks a significant step forward in our commitment to expand access to infectious disease diagnostics across the U.S., and builds on the expansion efforts for this system in other areas of the world," said Nadia Aelbrecht, Vice President and Head of Infectious Diseases at QIAGEN. "QIAstat-Dx builds on the strong customer response to the lower-throughput version, empowering labs to automate and scale up testing with minimal hands-on time while delivering the detailed diagnostic insights needed for timely treatment decisions."

    This clearance marks QIAGEN's third FDA-cleared QIAstat-Dx product in 2025, and builds on a growing portfolio of six panels cleared for the QIAstat-Dx family over the last 12 months. The system is already available in more than 100 countries, with over 4,600 instruments placed globally through the first half of 2025.

    The first two panels for respiratory conditions are already available. QIAGEN also plans to add to the QIAstat-Dx Rise system in the coming months its family of gastrointestinal panels including the QIAstat-Dx Gastrointestinal Panel 2, QIAstat-Dx Gastrointestinal Mini B&V and QIAstat-Dx Gastrointestinal Panel Mini B. Additional panels for both QIAstat-Dx and QIAstat-Dx Rise are in development.

    QIAstat-Dx Rise delivers automated, real-time PCR-based detection of multiple pathogens from a single sample, significantly increasing testing capacity while maintaining the speed and ease of use that QIAstatDx is known for. With the ability to run up to 160 tests per day across eight analytical modules – including 16 batch samples and two urgent slots per run – the system enables fast and accurate diagnoses in settings where turnaround time is critical.

    QIAstat-Dx quickly multiplies many genetic targets using real-time PCR technology in the same reaction, delivering results in about one hour and with less than one minute of hands-on time. Cycle threshold (Ct) values and amplification curves provide laboratories with additional information in the context of co-infections, and are instantly viewable on the instrument touchscreen with no additional software required.

    To learn more about QIAGEN's range of QIAstat-Dx devices and testing panels, visit https://www.qiagen.com/applications/syndromic-testing.

    About QIAGEN

    QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and Molecular Diagnostics (clinical healthcare). As of June 30, 2025, QIAGEN employed approximately 5,700 people across more than 35 locations. For more information, visit www.qiagen.com.

    Forward-Looking Statement

    Certain statements in this press release may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements, including those regarding QIAGEN's products, development timelines, marketing and/or regulatory approvals, financial and operational outlook, growth strategies, collaborations and operating results, such as expected adjusted net sales and adjusted diluted earnings, are based on current expectations and assumptions. However, they involve uncertainties and risks. These risks include, but are not limited to, challenges in managing growth and international operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies), variability in operating results, and the commercial development of products for customers in the Life Sciences and clinical healthcare markets; changes in relationships with customers, suppliers or strategic partners; competition and rapid technological change; fluctuating demand for QIAGEN's products due to factors such as economic conditions, customer budgets and funding cycles; obtaining and maintaining product regulatory approvals; and challenges in integrating QIAGEN's products into manufacturing process workflows and manufacturing at scale. Additional risks include market acceptance of new products, integration of acquisitions, governmental actions, global or regional economic developments, natural disasters, political or public health crises, and other force majeure events. There is also no guarantee that anticipated benefits from restructuring programs and acquisitions will materialize as expected. For a more complete discussion of risks and uncertainties, please refer to the "Risk Factors" section in our most recent Annual Report on Form 20-F and other reports filed with or furnished to the U.S. Securities and Exchange Commission.

    Source: QIAGEN N.V.

    Category: Infectious Diseases

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250901414875/en/

    Contacts QIAGEN:

    Investor Relations

    e-mail: [email protected]

    Public Relations

    e-mail: [email protected]

    Get the next $QGEN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $QGEN

    DatePrice TargetRatingAnalyst
    6/24/2025$55.00Overweight
    Barclays
    4/4/2025Buy → Neutral
    Redburn Atlantic
    2/19/2025$52.00 → $42.00Outperform → Neutral
    Robert W. Baird
    1/6/2025$48.00Overweight → Equal-Weight
    Morgan Stanley
    12/10/2024$42.50 → $54.00Hold → Buy
    Jefferies
    10/17/2024$49.00Buy → Hold
    HSBC Securities
    6/27/2024$50.00Peer Perform → Outperform
    Wolfe Research
    12/19/2023$44.00Equal Weight
    Wells Fargo
    More analyst ratings

    $QGEN
    SEC Filings

    View All

    SEC Form 6-K filed by Qiagen N.V.

    6-K - QIAGEN N.V. (0001015820) (Filer)

    8/29/25 6:12:04 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 6-K filed by Qiagen N.V.

    6-K - QIAGEN N.V. (0001015820) (Filer)

    8/21/25 5:20:49 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Qiagen N.V.

    SCHEDULE 13G/A - QIAGEN N.V. (0001015820) (Subject)

    8/12/25 10:34:25 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QGEN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    QIAGEN Gains U.S. Clearance of Higher-Throughput QIAstat-Dx Rise, Expanding Patient Access to Rapid Syndromic Testing

    U.S. market entry set to begin for QIAstat-Dx Rise – a version of QIAstat-Dx for syndromic testing that combines unparalleled throughput with the easiest workflow QIAstat-Dx Rise launch can process up to 160 samples per day, initial launch includes Respiratory Panel Plus and Respiratory Panel Mini and additional panels in development Expansion of QIAstat-Dx instrument portfolio in the U.S. builds on the availability of both system options in Europe and other regions of the world QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the launch of QIAstat‑Dx Rise – a version of the QIAstat-Dx automated syndromic testing system that offers unparalled throughput with

    9/2/25 1:30:00 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability

    Q2 2025 results: Net sales of $534 million (+7% actual rates); adjusted diluted EPS of $0.60 Net sales +6% CER (constant exchange rates) above outlook for at least +5% CER and adjusted diluted EPS of $0.62 CER above outlook for at least $0.60 CER 29.9% adj. operating income margin up 1.5 percentage points vs. 28.4% in Q2 2024 Diagnostic solutions sales +11% CER, driven by QIAstat-Dx (+41% CER) and QuantiFERON (+11% CER) and companion diagnostic partnerships 2025 net sales outlook increased to +4-5% CER (prior about +4% CER) and +5-6% CER core sales (prior about +5% CER); adj. diluted EPS outlook reaffirmed for about $2.35 CER QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standar

    8/5/25 4:05:00 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    QIAGEN Expands NGS Portfolio with Launch of QIAseq xHYB Long Read Panels

    Expansion of QIAseq portfolio to Long Read Panels enables high-resolution analysis of complex genomic regions using long-read sequencing Supports NGS platforms such as PacBio for applications including structural variants, HLA typing and repeat expansions QIAGEN supporting fully integrated workflow from best-in-class sample preparation through to powerful bioinformatics for analysis and interpretation QIAGEN (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced the launch of its new QIAseq xHYB Long Read Panels, a suite of target enrichment solutions designed to unlock long-read sequencing of genomically complex regions. This new offering strengthens QIAGEN's position as a

    7/22/25 4:05:00 PM ET
    $PACB
    $QGEN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Qiagen with a new price target

    Barclays initiated coverage of Qiagen with a rating of Overweight and set a new price target of $55.00

    6/24/25 8:09:28 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Qiagen downgraded by Redburn Atlantic

    Redburn Atlantic downgraded Qiagen from Buy to Neutral

    4/4/25 8:39:19 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Qiagen downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Qiagen from Outperform to Neutral and set a new price target of $42.00 from $52.00 previously

    2/19/25 7:04:54 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QGEN
    Leadership Updates

    Live Leadership Updates

    View All

    Neogen Announces the Appointment of New Board Member

    LANSING, Mich., Oct. 1, 2024 /PRNewswire/ -- Neogen® Corporation (NASDAQ:NEOG), an innovative leader in food safety solutions, announced today that it has appointed Thierry Bernard as a director to its Board, effective November 1, 2024. "We are pleased to welcome Thierry Bernard to the Neogen Board of Directors and look forward to his guidance as the company continues in its commitment to fueling a brighter future for global food security," said Jim Borel, Neogen's Board Chair. "As a sitting CEO with a wealth of knowledge in science and technologies relevant to Neogen and its

    10/1/24 8:45:00 AM ET
    $NEOG
    $QGEN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Actym Therapeutics Appoints Chan Whiting as Chief Development Officer

    BERKELEY, Calif., Nov. 11, 2021 /PRNewswire/ -- Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors.   Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer."Chan has significant experience advancing novel cancer

    11/11/21 9:00:00 AM ET
    $QGEN
    $TPST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Quotient Limited Announces Appointment of Chief Commercial Officer

    JERSEY, Channel Islands, Oct. 05, 2021 (GLOBE NEWSWIRE) --  Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Company's Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it continues to expand globally. "I am delighted to welcome a strong and experienced commercial leader like Mohammad to the Executive team. During the last 30 years, he has been partnering with customers across the globe. Mohammad will be instrumental in accelerating the commercialization of our MosaiQ solution. He will continue to build the commercial team and expand the distribution channels whil

    10/5/21 7:45:00 AM ET
    $QGEN
    $QTNT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $QGEN
    Financials

    Live finance-specific insights

    View All

    QIAGEN exceeds outlook for Q2 2025 with solid growth and improved profitability

    Q2 2025 results: Net sales of $534 million (+7% actual rates); adjusted diluted EPS of $0.60 Net sales +6% CER (constant exchange rates) above outlook for at least +5% CER and adjusted diluted EPS of $0.62 CER above outlook for at least $0.60 CER 29.9% adj. operating income margin up 1.5 percentage points vs. 28.4% in Q2 2024 Diagnostic solutions sales +11% CER, driven by QIAstat-Dx (+41% CER) and QuantiFERON (+11% CER) and companion diagnostic partnerships 2025 net sales outlook increased to +4-5% CER (prior about +4% CER) and +5-6% CER core sales (prior about +5% CER); adj. diluted EPS outlook reaffirmed for about $2.35 CER QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standar

    8/5/25 4:05:00 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    QIAGEN N.V. to Release Results for Q2 2025 and Hold Webcast

    QIAGEN N.V. (NYSE:QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2025. Press release date / time: Tuesday, August 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time. Conference call date / time: Wednesday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time. Three options for joining the conference call Register for call back connection - Click here: Connect me Service is available 15 minutes before the call starts Dial-in by phone U.S.: +1 929 477 0402 UK: +44 (0)330 165 3655 GER: +49 (0)69 6610 2480 Conference ID: 1992038 To avoid waiting time, please join the event co

    7/8/25 5:44:00 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    QIAGEN Announces Election of Stephen Rusckowski as Chairman of Supervisory Board

    Stephen H. Rusckowski elected as Chairman of the Supervisory Board after AGM; former Chairman Lawrence A. Rosen did not stand for re-election following 12 years of service Shareholders approve all resolutions at AGM – including first-ever annual cash dividend and a synthetic share repurchase authorization of up to $500 million QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced that its Supervisory Board has elected Stephen H. Rusckowski as Chairman following the Annual General Meeting of Shareholders (AGM) on June 26, 2025. He succeeds Lawrence A. Rosen, who did not stand for re-election after serving for 12 years on the Supervisory Board. The Dutch Corporate G

    6/26/25 1:16:00 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $QGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Qiagen N.V.

    SC 13G - QIAGEN N.V. (0001015820) (Subject)

    11/8/24 10:52:38 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Qiagen N.V. (Amendment)

    SC 13G/A - QIAGEN N.V. (0001015820) (Subject)

    2/9/24 11:49:03 AM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed by Qiagen N.V. (Amendment)

    SC 13G/A - QIAGEN N.V. (0001015820) (Subject)

    12/6/23 12:35:32 PM ET
    $QGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care